Tyra Biosciences, Inc.
Financials
Valuation Metrics
Tyra Biosciences, Inc.'s Market Cap is $1.27B. At end of 2025 it was $1.57B. Ranked #2268 of 3,114 in US market (top 73%), #906 of 1,472 on NASDAQ (top 62%), #169 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 64%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.27B | US#2,268/3,114 Sec#169/265 |
| Revenue | $0.00 | US#2,862/3,114 Sec#193/265 |
| Net Income | $-149M | US—/3,114 Sec—/265 |
| Total Assets | $383M | US#2,853/3,114 Sec#191/265 |
| Net Assets | $354M | US#2,436/3,114 Sec#145/265 |
| Employees | 87 | US#2,642/3,114 Sec#185/265 |
| Value | ||
| P/B | 3.59x | US#1,964/3,114 Sec#115/265 |
| FCF Yield | -8.65% | US—/3,114 Sec—/265 |
| Profitability | ||
| ROE | -42.01% | US#2,636/3,114 Sec#141/265 |
| ROA | -38.75% | US#2,940/3,114 Sec#189/265 |
| Financial Health | ||
| Debt Ratio | 8.40% | US#82/3,114 Sec#38/265 |
| Total Debt | $6M | US#2,885/3,114 Sec#211/265 |
| FCF | $-110M | US#2,652/3,114 Sec#152/265 |
| Cash | $74M | US#2,394/3,114 Sec#198/265 |
| Current Ratio | 14.91x | US#167/3,114 Sec#50/265 |
| Performance | ||
| 1Y Return | 34.85% | US#515/3,114 Sec#71/265 |
| 1M Return | 4.55% | US#1,756/3,114 Sec#124/265 |
| From 52W High | -47.45% | US#2,583/3,114 Sec#191/265 |
| 1Y MDD | -53.24% | US#2,522/3,114 Sec#182/265 |
| Trading | ||
| Volume | 440,583 shares | US#1,998/3,114 Sec#208/265 |
| Trading Value | $9M | US#2,255/3,114 Sec#180/265 |
| Per Share | ||
| EPS | $-2.50 | US—/3,114 Sec—/265 |
| BPS | $5.95 | US#2,193/3,114 Sec#111/265 |
Company Info
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.